The closing price of Voyager Therapeutics Inc (NASDAQ: VYGR) was $9.26 for the day, up 2.77% from the previous closing price of $9.01. In other words, the price has increased by $+0.25 from its previous closing price. On the day, 661557 shares were traded.
Ratios:
Our analysis of VYGR’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.73. For the most recent quarter (mrq), Quick Ratio is recorded 4.96 and its Current Ratio is at 4.96. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 19, 2024, initiated with a Buy rating and assigned the stock a target price of $30.
On March 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $16.
Wells Fargo Upgraded its Equal Weight to Overweight on January 02, 2024, while the target price for the stock was maintained at $14.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 21 ’24 when Sandrock Alfred sold 13,033 shares for $7.46 per share. The transaction valued at 97,226 led to the insider holds 334,954 shares of the business.
Swartz Robin sold 3,966 shares of VYGR for $29,547 on Feb 21 ’24. The Chief Operating Officer now owns 118,361 shares after completing the transaction at $7.45 per share. On Feb 21 ’24, another insider, PFREUNDSCHUH PETER P., who serves as the Chief Financial Officer of the company, sold 3,764 shares for $7.46 each. As a result, the insider received 28,079 and left with 175,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 488.71M and an Enterprise Value of 278.12M. As of this moment, Voyager’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01 while its Price-to-Book (P/B) ratio in mrq is 1.73. Its current Enterprise Value per Revenue stands at 1.11 whereas that against EBITDA is 2.20.
Stock Price History:
Over the past 52 weeks, VYGR has reached a high of $14.34, while it has fallen to a 52-week low of $6.06. The 50-Day Moving Average of the stock is 8.22, while the 200-Day Moving Average is calculated to be 8.61.
Shares Statistics:
VYGR traded an average of 967.31K shares per day over the past three months and 1.05M shares per day over the past ten days. A total of 44.04M shares are outstanding, with a floating share count of 42.78M. Insiders hold about 21.22% of the company’s shares, while institutions hold 48.34% stake in the company. Shares short for VYGR as of Feb 29, 2024 were 2.26M with a Short Ratio of 2.34, compared to 1.97M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.17% and a Short% of Float of 4.98%.
Earnings Estimates
The firm’s stock currently is rated by 8 analysts. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.52, while EPS last year was $2.94. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.32 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$0.6 and -$2.9 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$1.8, with 8 analysts recommending between $0.15 and -$4.18.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $16M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $150.48M, an estimated decrease of -93.80% from the year-ago figure.
A total of 9 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $90.14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $39.82M. In the same quarter a year ago, actual revenue was $250.01M, down -84.10% from the average estimate.
